Box of Selincro Tablets used to reduce alcohol consumption

Selincro Tablets

£54.99

Selincro Tablets are used to support the reduction of alcohol consumption in adults with high-risk drinking patterns. They reduce alcohol craving and reward effects when taken as needed.
Packaging and branding may differ from image shown.

Start Assessment

Description

Selincro Tablets are a prescription medication used to support the reduction of alcohol consumption in adults with alcohol dependence. It is suitable for patients with a high drinking risk level who do not need immediate detoxification or abstinence but wish to lower their alcohol intake over time with medical support.

How It Works

The active ingredient in Selincro is nalmefene, which acts as a modulator of opioid receptors in the brain. It works by altering the reward signals associated with alcohol consumption, making drinking less satisfying. This pharmacological action helps reduce cravings and lowers the urge to consume excessive amounts of alcohol, particularly in individuals who drink habitually and excessively.

Why Choose Selincro Tablets

Selincro is the first licensed treatment specifically indicated to help reduce, rather than stop, alcohol consumption in dependent adults. It is taken only on days when drinking is anticipated, which gives users flexibility and supports gradual reduction. Clinical studies have shown a significant reduction in daily alcohol intake and improved control over drinking habits in patients using Selincro alongside psychosocial support.

Important Note

Selincro is not intended for those requiring immediate abstinence or detox. It should not be used in individuals taking opioid pain medications or undergoing opioid replacement therapy. Patients should be monitored regularly to assess drinking patterns and treatment response. Common side effects such as dizziness or nausea may occur, particularly when first starting treatment. Always follow the dosing schedule and consult your doctor regularly during use.

Directions

Please refer to the medication’s patient information leaflet before starting any new medication.

  • Take one tablet 1–2 hours before anticipated alcohol consumption

  • Do not exceed one tablet per day

  • Swallow whole with water, with or without food
    Storage instructions:

  • Store below 25°C

  • Keep in original packaging

  • Keep out of reach of children

Ingredients

Active Ingredient:

  • Nalmefene hydrochloride 18.06mg (equivalent to nalmefene 18mg)

Other Ingredients:

  • Lactose monohydrate

  • Cellulose microcrystalline

  • Croscarmellose sodium

  • Magnesium stearate

  • Hypromellose

  • Titanium dioxide

  • Macrogol

Side Effects

Common side effects may include:

  • Nausea

  • Dizziness

  • Insomnia

Serious (rare) side effects:

  • Hallucinations

  • Confusion

  • Liver function changes

Stop the medicine and seek medical attention if serious side effects occur.

Warnings

Do not take Selincro if you are taking opioids or have recently used opioid-based medication. Not suitable for individuals with severe liver or kidney impairment. Use caution in patients with psychiatric disorders. Always consult a healthcare provider before starting Selincro, especially if undergoing other treatments for alcohol dependence.

  • Selincro may interact with other medications, especially those affecting the central nervous system. Always inform your doctor about all medications before starting treatment.

  • Selincro contains nalmefene, an opioid receptor modulator that alters the brain’s reward response to alcohol. It reduces the urge to drink and limits the rewarding effects of alcohol.

  • Selincro contains nalmefene, which changes how the brain reacts to alcohol. It reduces the urge to drink and makes alcohol less rewarding, making it easier to stick to alcohol reduction goals.

  • Take one tablet on days when you anticipate drinking alcohol, ideally 1–2 hours before the first drink. Do not exceed one tablet per day.

  • Selincro is not suitable for individuals with severe liver or kidney disease, those on opioid therapy, or individuals experiencing acute alcohol withdrawal. Medical assessment is required before starting.